Literature DB >> 29935236

Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis.

Alessandro Mantovani1, Marco Dauriz1, Christopher D Byrne2, Amedeo Lonardo3, Giacomo Zoppini1, Enzo Bonora1, Giovanni Targher4.   

Abstract

BACKGROUND: It is currently uncertain whether non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of colorectal tumours. We performed a meta-analysis of relevant observational studies to quantify the magnitude of the association between NAFLD and risk of colorectal adenomas and cancer.
METHODS: We searched PubMed, Scopus and Web of Science from January 2000 to November 2017 using pre-defined keywords to identify observational studies of asymptomatic adults undergoing screening colonoscopy, in which NAFLD was diagnosed by imaging or histology. Data from selected studies were extracted and meta-analysis was performed using random-effects modelling.
RESULTS: Eleven observational studies (8 cross-sectional and 3 longitudinal) with aggregate data on 91,124 asymptomatic adults (32.1% with NAFLD) of predominantly Asian descent accounting for a total of 14,911 colorectal adenomas and 1684 cancers were included in the final analysis. NAFLD was associated with an increased risk of prevalent colorectal adenomas (n = 7 studies using liver imaging techniques; random-effects odds ratio [OR] 1.28, 95% CI 1.11-1.48; I2 = 82.9% or n = 1 study using liver biopsy; random-effects OR 1.61, 95% CI 0.90-2.89) and cancer (n = 4 studies using liver imaging techniques; random-effects OR 1.56, 95% CI 1.25-1.94; I2 = 65.6% or n = 1 study using liver biopsy; random-effects OR 3.04, 95% CI 1.29-7.18). NAFLD was also associated with an increased risk of incident colorectal adenomas (n = 3 studies; random-effects hazard ratio [HR] 1.42, 95% CI 1.18-1.72; I2 = 0%) and cancer (n = 1 study; random-effects HR 3.08, 95% CI 1.02-9.03). These risks were independent of age, sex, smoking, body mass index and diabetes (or metabolic syndrome). Sensitivity analyses did not alter these findings. Funnel plot and Egger's test did not reveal significant publication bias.
CONCLUSIONS: This meta-analysis of observational studies (involving asymptomatic individuals of predominantly Asian descent undergoing screening colonoscopy) suggests that NAFLD (detected by imaging or biopsy) is independently associated with a moderately increased prevalence and incidence of colorectal adenomas and cancer. However, the observational design of the studies does not allow for proving causality, and the possibility of residual confounding by some unmeasured factors cannot be ruled out. More prospective studies, particularly in European and American individuals, and mechanistic studies are required to better understand the association between NAFLD and colonic carcinogenesis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Colorectal tumours; Meta-analysis; NAFLD

Mesh:

Year:  2018        PMID: 29935236     DOI: 10.1016/j.metabol.2018.06.004

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  28 in total

1.  The "obese liver" and gastrointestinal cancer risk.

Authors:  Amedeo Lonardo; Luca Roncucci
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

Review 2.  Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia.

Authors:  Michael W Gleeson
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

Review 3.  Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.

Authors:  Naga S Samji; Rajanshu Verma; Sanjaya K Satapathy
Journal:  J Clin Exp Hepatol       Date:  2019-05-16

Review 4.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

5.  Multiple Mechanisms of Shenqi Pill in Treating Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Molecular Docking.

Authors:  Xiaojuan Tong; Sumei Xu; Dong Zhai
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-26       Impact factor: 2.650

Review 6.  Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations.

Authors:  Alexander J Kovalic; George Cholankeril; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2019-09-03

Review 7.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.

Authors:  Eda Kaya; Yusuf Yilmaz
Journal:  J Clin Transl Hepatol       Date:  2021-10-19

8.  Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.

Authors:  Shuhei Fukunaga; Dan Nakano; Takumi Kawaguchi; Mohammed Eslam; Akihiro Ouchi; Tsutomu Nagata; Hidefumi Kuroki; Hidemichi Kawata; Hirohiko Abe; Ryuichi Nouno; Koutaro Kawaguchi; Jacob George; Keiichi Mitsuyama; Takuji Torimura
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

Review 9.  Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers.

Authors:  Shabnam Shalapour; Michael Karin
Journal:  Annu Rev Immunol       Date:  2020-02-10       Impact factor: 32.481

10.  Value of routine test for identifying colorectal cancer from patients with nonalcoholic fatty liver disease.

Authors:  Rong Yang; Yu Chen; Xianlai Chen
Journal:  BMC Gastroenterol       Date:  2020-06-09       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.